GENTROPIN ONE ® 252 IU by Omega 1 Pharma is Human Growth Hormone - Somatropin (rDNA origin).

Content:
7 vials with Somatropin lyophilized powder.
7 vials with Solution for injection 2 ml.
 
Human Growth Hormone
Each vial with lyophilized Each powder contains:
Somatropin 12 mg equivalent to 36 IU.
 
Solution for Injection:
Each vial of solution contains:
0.9% sodium chloride solution 2 ml.

GENTROPIN ONE ®  makes a small protein that is made by the pituitary gland and secreted into the bloodstream. GENTROPIN ONE ®  production is controlled by a complex set of hormones produced in the hypothalamus of the brain and in the intestinal tract and pancreas.

The pituitary puts out GENTROPIN ONE ®  in bursts; levels rise following exercise, trauma, and sleep. Under normal conditions, more GENTROPIN ONE ®  is produced at niGENTROPIN ONE ® t than during the day. This physiology is complex, but at a minimum, it tells us that sporadic blood tests to measure GENTROPIN ONE ®  levels are meaningless since Growth Hormone and low levels alternate somatropin out the day. But scientists who carefully measure overall Human Growth Hormone production report that it rises during childhood, peaks during puberty, and declines from middle age onward.

GENTROPIN ONE ®  acts on many tissues somatropin out the body. In children and adolescents, it stimulates the growth of bone and cartilage. In people of all ages, GENTROPIN ONE ®  boosts protein production, promotes the utilization of fat, interferes with the action of insulin, and raises blood sugar levels. GENTROPIN ONE ®  also raises levels of insulin-like growth factor-1 (IGF-1).

Therapeutic indications

Children and adolescents:

- In the treatment of children with short stature associated with growth retardation due to a decrease or
absence of endogenous growth hormone secretion.

- In the treatment of growth retardation in girls with gonadal dysgenesis (also known as Turner
syndrome), confirmed by chromosomal analysis.

- In the treatment of growth retardation in prepubertal children with chronic renal failure (CRF).

- Growth disorders (current height standard deviation score (SDS) <- 2.5 and parents' standard deviation score to be reached <-1) in children born small for gestational age (SGA), whose weight and / or height at birth was <-2.0 of standard deviation with respect to gestational age and that until the age of 4 or more they have not yet recovered this delay in growth (growth rate with standard deviation score SDS <0 in the last year) at 4 years of age or later.

Adults:

- Replacement therapy in adults with pronounced growth hormone deficiency diagnosed by individual dynamic test for growth hormone deficiency.

Patients must meet the following criteria:

Onset in childhood: Patients who were diagnosed with growth hormone deficiency during childhood should be clinically evaluated and their growth hormone deficiency confirmed before replacement therapy
with GENTROPIN ONE ®  is started.

Onset in adulthood: Patients must have growth hormone deficiency as a result of pituitary or hypothalamic disease and at least one other diagnosed hormone deficiency (except prolactin), and appropriate replacement therapy instituted, before initiation replacement therapy using growth hormone.

Dose: Under medical prescription only. Administration: Subcutaneous.

Storage indications: Keep at no more than 30°C. Made the mixture refrigerated at 2°-8°C.

Keep out of reach of children. Do not use in pregnancy or breastfeeding.